Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has earned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $10.00.

A number of research firms have weighed in on AMRX. Piper Sandler upped their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th.

Amneal Pharmaceuticals Trading Down 1.5 %

Shares of NASDAQ:AMRX opened at $7.85 on Monday. The stock has a 50 day moving average of $8.13 and a 200 day moving average of $8.24. The company has a market cap of $2.43 billion, a PE ratio of -11.54 and a beta of 1.10. Amneal Pharmaceuticals has a 12-month low of $5.01 and a 12-month high of $9.48.

Insider Transactions at Amneal Pharmaceuticals

In related news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares in the company, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total value of $139,454.10. Following the transaction, the director now owns 2,031,476 shares of the company’s stock, valued at $16,272,122.76. This represents a 0.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 203,657 shares of company stock valued at $1,667,887. 26.56% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AMRX. JPMorgan Chase & Co. increased its holdings in shares of Amneal Pharmaceuticals by 149.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after buying an additional 777,568 shares during the last quarter. Barclays PLC increased its stake in Amneal Pharmaceuticals by 134.1% during the third quarter. Barclays PLC now owns 296,384 shares of the company’s stock worth $2,466,000 after acquiring an additional 169,756 shares during the last quarter. State Street Corp raised its position in Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock valued at $29,242,000 after purchasing an additional 127,753 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $520,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after purchasing an additional 378,136 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.